QUILT-2.013: First-Line Treatment for Extensive Stage Small Cell Lung Cancer

Key Inclusion Criteria * Histologically or cytologically confirmed SCLC * Extensive disease, defined by at least one of the following: * No limited disease (ie, no disease confined to the ipsilateral hemithorax, which can be safely encompassed within a tolerable radiation field) * Extrathoracic metastases * Malignant pericardial or pleural effusion * Contralateral hilar adenopathy * Measurable or nonmeasurable disease, as defined by modified RECIST * Eastern Cooperative Oncology Group (ECOG) status 0 or 1 * ≥18 years old * Life expectancy (with therapy) ≥3 months * Adequate hematologic, hepatic, coagulation, renal, and metabolic function * Diabetes, if present, must be controlled, with glycosylated hemoglobin (HbA1C) ≤ 8% and fasting glucose levels ≤160 mg/dL Key Exclusion Criteria * Prior chemotherapy, chemoradiation, or investigational agent for SCLC * Prior radiotherapy to \>25% of the bone marrow * Symptomatic or untreated central nervous system metastases (with exceptions) * Currently or previously treated with biologic, immunologic or other therapies for SCLC * Current serious or nonhealing wound or ulcer * History of prior concurrent other malignancy (with exceptions) * Thorombosis or vascular ischemic events within the last 12 months such as DVT, PE, TIA or MI * Any clinically significant medical condition other than cancer (eg, cardiovascular disease or COPD), which could interfere with the safe delivery of study treatment or risk of toxicity